Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On May 10, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and provided a business update.</li><li> Edesa is planning to seek regulatory approval for a Phase 2 trial of its anti-CXCL10 mAb in patients with moderate-to-severe nonsegmental vitiligo.</li><li>For EB05, the company has expanded site selection activities for the Phase 3 study in acute respiratory distress syndrome (ARDS) caused by COVID-19 and has begun transitioning the day-to-day management of the trial to a new clinical research organization (CRO).</li></ul>

On May 10, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and provided a business update. Edesa is planning to seek regulatory approval for a Phase 2 trial of its anti-CXCL10 mAb in patients with moderate-to-severe nonsegmental vitiligo.For EB05, the company has expanded site selection activities for the Phase 3 study in acute respiratory distress syndrome (ARDS) caused by COVID-19 and has begun transitioning the day-to-day management of the trial to a new clinical research organization (CRO).

EDSA: Preparing IND for Phase 2 Trial of EB06 in Vitiligo 

United States

Calithera Biosciences, Inc. provides pharmaceutical products. The Company is focused on discovering and developing novel small molecule drugs against tumor metabolism and immunology for the treatment of cancer. Calithera Biosciences serves patrients in the United States.

Cara Therapeutics, Inc. develops therapeutics. The Company offers novel drugs for the treatment of human diseases associated with pain and inflammation. Cara Therapeutics serves customers in the United States.

Organovo Holdings, Inc. operates as a biology company. The Company focuses on bio-printing technology and creating tissues for research and medical applications.

Tonix Pharmaceuticals Holding Corp. is a pharmaceutical company that develops therapies for disorders of the central nervous system ("CNS").  The Company develops therapies for disorders that include fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD"),

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company produces differentiated drugs that helps patients suffering from cancer, severe asthma, anemia, and other medical conditions. Pieris Pharmaceuticals serves customers worldwide.

KALA BIO, Inc. operates as a clinical-stage biopharmaceutical company. The Company designs and develops proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts, and the female reproductive systems. KALA BIO markets its products worldwide.

Calyxt, Inc. provides agricultural biotechnology services. The Company researches and develops seeds and food ingredients for agricultural, feed, and food applications, as well as offers fat saturation and gluten reduction in soybean oil and wheat. Calyxt markets its products in the United States.

Evelo Biosciences, Inc. operates as a bio-technology company. The Company develops therapies for the treatment of the gut-body network. Evelo Biosciences also offers treatment for cancer and inflammatory diseases. Evelo Biosciences serves customers in the State of Massachusetts.

Bellicum Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company focuses on discovering and developing novel cellular immunotherapies for cancer, tumors, and blood diseases. Bellicum Pharmaceuticals serves patients in the United States.

Aravive, Inc. operates as a biotechnology company. The Company develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. Aravive serves patients in the United States.

Biosino Bio-Technology & Science, Inc. is a biotechnology company.  The Company develops, manufactures, and markets protein-based in-vitro diagnostic reagents and biochemical drugs.  The Company's diagnostic reagents help diagnose cardiac, helatic, diabetes, inflammation/immunology, and pancreatic related diseases.

Immuron Limited operates as a biopharmaceutical company. The Company focuses on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron's technology platform is developing and producing an orally stable therapeutic for various immune mediated and inflammatory disorders.

Alterity Therapeutics Limited operates as a biotechnology company. The Company researches and develops therapeutic drugs used for treatment of alzheimer's diseases and age related disorders. Alterity Therapeutics serves patients in Australia.

Patrys Limited develops therapies for the capture, production, and development of natural human antibodies as therapies for cancer and other diseases.

Algorae Pharmaceuticals Limited operates as a clinical-stage pharmaceutical company. The Company focuses on research and development programs to accelerate patient access to novel drugs and therapies using the latest technologies and scientific innovations. Algorae Pharmaceuticals offers its services worldwide.

D.Western Therapeutics Institute Inc.(DWTI) is a biotechnology (bio-venture) company that focuses on development of new drugs. The Company's focus is on protein kinase inhibitors. DWTI discovers and develops several drugs, such as antiglaucoma, antihypertensive, neuroprotective, antithrombogenic, antiatherosclerosis and anticancer.

D.Western Therapeutics Institute Inc. (4576 JP)

Bionomics Limited operates as a biotechnology company, which specializes in the genetics field.  The Company, which is affiliated with a number of research institutions, seeks to develop a variety of genomic, genetic, molecular and cell biology techniques, which they believe will help demonstrate the onset and progression of diseases like epilepsy and breast cancer.

Bharat Immunologicals & Biologicals Corporation Ltd. manufactures and distributes pharmaceutical drugs and vaccines. The Company's primary product is oral polio vaccine (OPV).

Oncimmune Limited develops and commercializes products for the detection of cancerous. It develops autoantibody assay technologies that have the potential to early detection a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test that is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company is based in Nottingham, the United Kingdom.

Celyad Oncology SA is a bio-pharmaceutical company. The Company specialized in CAR-T cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis, such as cancer. Celyad Oncology serves customers worldwide.

Edesa Biotech, Inc. operates as a clinical-stage biopharmaceutical company. The Company offers drugs for the treatment of dermatological and gastrointestinal diseases including alternatives to topical steroids. Edesa Biotech serves patients in the United States and Canada.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Edesa Biotech (EDSA US)

EDSA: Preparing IND for Phase 2 Trial of EB06 in Vitiligo

On May 10, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the second quarter of fiscal year 2024 that ended March 31, 2024 and...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)